Scalper1 News
Shares of big pharma AbbVie (ABBV) dropped more than 3% Friday morning after the company issued 2015 EPS guidance and got downgraded by Bank of America. AbbVie said it expects full-year earnings of $4.25 to $4.45, the midpoint just above the average estimate of $4.32 among analysts polled by Thomson Reuters. The company said it will further refine guidance as it rolls out its new hepatitis C treatment Viekira Pak, which launched in America last Scalper1 News
Scalper1 News